EVEREST MED (01952) Weishiping has been approved by the National Medical Products Administration to be launched, opening a new era of oral treatment for moderate to severe ulcerative colitis.

On February 6, 2026, Everest MED, an innovative pharmaceutical company in the Hong Kong stock market, announced that its core product Velsipity (L-arginine amisulpride tablets, VELSIPITY) in the field of autoimmune diseases has been approved for listing by the National Medical Products Administration (NMPA) of China. It is used to treat moderate to severe active ulcerative colitis (UC) in adults who have inadequate response to traditional treatments or biologics, are non-responsive, or intolerant. As a new generation of highly selective S1P receptor modulator, Velsipity is taken orally once a day and can achieve fast and potent mucosal healing. It has good safety characteristics and the potential to be the best-in-disease, providing a new first-line treatment option for adult patients with ulcerative colitis. The commercial prospects are highly optimistic within the industry, with forecasted peak sales reaching 5 billion RMB, making it another core product for Everest MED after Nifukang in the field of kidney disease. This move also indicates a new round of rapid growth in its commercialization strategy. The CEO of Everest MED, Yongqing Luo, stated that the approval of Velsipity in China fills an important gap in the treatment of moderate to severe ulcerative colitis and provides a new choice for innovative oral treatment aimed at deep mucosal healing. The company will accelerate the commercialization process of Velsipity and actively promote its inclusion in the national medical insurance catalog, continuously improving the accessibility and affordability of innovative therapies in China to benefit more patients. Velsipity fills a clinical gap and promotes the upgrade of UC chronic disease management. In recent years, the incidence of ulcerative colitis in China has been steadily increasing and showing a trend towards a younger demographic. It is estimated that the number of patients will increase from about 980,000 in 2025 to about 1.5 million by 2031. However, traditional therapies in China have long faced limitations such as limited efficacy, high recurrence rates, poor convenience of administration, and numerous adverse reactions. Approved biologics and small molecule therapies also encounter issues like "efficacy ceiling" and "non-response". Mucosal healing is a core treatment goal for UC as defined by authoritative guidelines and consensus both domestically and internationally. However, it has long faced challenges with low achievement rates and high clinical difficulty in achieving it. The "2021-China IBD Blue Book China Inflammatory Bowel Disease Medical-Patient Awareness and Quality of Life Report" shows that only 24% of UC patients achieve mucosal healing, far from meeting clinical needs. According to Professor Kaichun Wu, head of the Asia-Pacific clinical trial of Velsipity, executive member and treasurer of the World Gastroenterology Organization, vice chairman of the Asia-Pacific Association of Digestive Diseases, and former deputy director of the 10th and 11th sessions of the Chinese Medical Association Digestive Society, "Velsipity controls intestinal inflammation by regulating lymphocyte migration and promotes mucosal healing. In multiple clinical studies, Velsipity has demonstrated significant efficacy, especially in rapid onset, achieving steroid-free remission and deep mucosal healing, with good safety and tolerability." Internationally recognized guidelines recommend Velsipity as first-line treatment. The mature commercialization platform will accelerate the market access and application of Velsipity. Professor Chen Minhoo, former chairman of the Chinese Medical Association Gastroenterology Branch, leader of the Inflammatory Bowel Disease Group, academic leader of the Department of Gastroenterology at the First Affiliated Hospital of Sun Yat-sen University, stated, "China is currently experiencing a rapid increase in the incidence and prevalence of ulcerative colitis. The disease often recurs, severely affecting the quality of life of patients and imposing a heavy burden on individuals, families, and healthcare resources. Achieving mucosal healing helps control symptoms more effectively, reduces the risk of recurrence, and improves the quality of life of patients. Mucosal healing is a recognized treatment goal for ulcerative colitis both domestically and internationally, which is closely related to long-term symptom relief and improving the quality of life of patients." "Velsipity, as a new generation of highly selective S1P receptor modulator, with a once-daily oral treatment plan, can quickly take effect, achieve clinical remission, and demonstrate significant efficacy in mucosal healing and histological improvement. It also has good safety, providing a new treatment option for moderate to severe active ulcerative colitis in adults," added Professor Chen Minhoo. Based on its outstanding clinical efficacy and good safety, the clinical value of Velsipity has been fully recognized by international authoritative guidelines. Currently, the drug has been included in the 2024 American Gastroenterological Association (AGA) Clinical Practice Guidelines and recommended as first-line treatment for ulcerative colitis. In June 2025, it was included in the "2025 ACG Clinical Guidelines for Adult Ulcerative Colitis" and strongly recommended for induction and maintenance treatment of moderate to severe active ulcerative colitis, fully reflecting the high recognition of its efficacy and safety by international authoritative academic institutions. Industry analysis indicates that with limited clinical treatment options, Velsipity has huge market potential. Furthermore, after years of deep cultivation, Everest MED has established an integrated A2MS operation system based on scientific and commercial insights, which will efficiently promote the market access of Velsipity and accelerate its application in the clinic, further unlocking the therapeutic value and market potential of the drug. Commercialization adds another core engine. Continuous optimization of revenue structure for the company. The approval of Velsipity marks a significant breakthrough for Everest MED in the field of autoimmune diseases, further enriching its commercial product matrix. As a new heavyweight single product, Velsipity is expected to reach peak sales of 5 billion RMB, significantly boosting the company's revenue and profitability along with its existing commercial products. In terms of commercialization progress, Velsipity has already gained a first-mover advantage. In 2024, the drug was included in the clinical urgently needed imported drugs and medical devices catalog for the 9 cities in the Guangdong-Hong Kong-Macao Greater Bay Area, achieving clinical application first in the Greater Bay Area. Currently, apart from mainland China, Velsipity has obtained new drug approval for listing in the United States, the European Union, as well as Hong Kong, Macao, Singapore, and other countries and regions. Additionally, Everest MED started the construction of the Velsipity Jiaxing factory in March 2025 to provide strong support for localized production and long-term accessibility. Everest MED's Board Chairman, Yifang Wu, stated, "Autoimmune diseases have a long-lasting and profound impact on patients globally, and there are still many unmet clinical needs in China and worldwide. The approval of Velsipity not only reflects the clinical value of innovative therapies in the treatment of ulcerative colitis but also demonstrates the company's long-term strategy of advancing the development of innovative drugs according to international research and development standards. We look forward to expanding our global footprint to benefit more patients with high-quality, breakthrough treatment options." The successful market launch of Velsipity will not only further support Everest MED in building a sustainable pipeline system with short-term returns, medium-term growth, and long-term potential, but also lay a solid foundation for the company's long-term and stable development. It will also strongly drive the 2030 strategic goals. According to Everest MED's 2030 development strategy, the company will focus on "BD cooperation + independent research and development" as a dual-wheel drive core, achieving revenue breakthrough of over 15 billion RMB by 2030, with more than 20 commercialized products, and ultimately aiming for a market value of over 100 billion RMB, positioning the company among the world's leading comprehensive biopharmaceutical companies. In terms of building a commercialization platform, Everest MED has laid out three commercial products and is actively establishing an all-channel commercialization system and lifecycle commercialization capabilities for drugs. The company expects to achieve revenue of over 10 billion RMB by 2028, with revenue surpassing 15 billion RMB by 2030 (including current pipeline sales revenue of approximately 9 billion RMB and new pipeline sales revenue of about 6 billion RMB); the compound annual growth rate is expected to exceed 50% from 2025 to 2030, and remain over 15% after 2030. At the same time, the number of commercialized products will continue to increase, including Nifukang, Velsipity, Yijia, Leriboh (Ledesibepp) and MT1013, fully supporting the growth goals. On the capital market level, the continuous landing of core products is expected to reshape the market's valuation expectations of the company. Coupled with the performance increment brought by global commercialization, Everest MED's risk resistance and growth certainty have significantly increased, with long-term investment value gradually being realized.